论文部分内容阅读
On a hot morning in July 2020,Liang Hongyang,deputy director of the No.6 Vaccine Office of the Beijing Institute of Biological Products(BJIBP)under China National Biotec Group(CNBG),a subsidiary of China National Pharmaceutical Group(Sinopharm),rushed int